Cellular Biomedicine Group to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
November 24, 2015 09:07 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Voting Results of 2015 Annual General Meeting
November 23, 2015 09:10 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Reports Third Quarter 2015 Financial Results and Provides Business Highlights
November 13, 2015 09:20 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 13, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group to Present HER-1-Targeted CAR-T Immunotherapy at CAR-T Summit 2015
November 11, 2015 09:18 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Opens New GMP Facility in Beijing
November 09, 2015 09:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
CBMG Responds to Inquiries From Investors and the Scientific Community About the Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma
November 03, 2015 09:20 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Presented Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma
October 28, 2015 16:01 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group to Present Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced Diffuse Large B Cell Lymphoma
October 23, 2015 08:15 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Calls for General Annual Stockholder Meeting on November 20, 2015
October 20, 2015 09:00 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Announces Positive Results From CAR-T EGFR Immunotherapy in Advanced Relapsed/Refractory Patients With Solid Tumors
September 28, 2015 08:56 ET
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and PALO ALTO, Calif., Sept. 28, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of...